(CHICAGO – May 6, 2017) – Dr. Richard B. Dorshow, Ph.D., Chief Scientific Officer of MediBeacon and Phillip I. Tarr MD, Director of the Division of Pediatric Gastroenterology, Hepatology and Nutrition at the Washington University School of Medicine and St. Louis Children’s Hospital presented the results of initial research focused on the measurement of gut permeability using MediBeacon fluorescent tracer agent technology at Digestive Disease Week 2017. The work was funded by a Phase I Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation to Washington University.
Together, Tarr and MediBeacon continue to pursue this innovative global health and development research project for monitoring human gut permeability under a Phase II Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation that was announced in October 2016.
Digestive Disease Week (DDW) is the world’s leading educational forum for academicians, clinicians, researchers, students and trainees working in gastroenterology, hepatology, GI endoscopy, gastrointestinal surgery and related fields. The conference draws approximately 15,000 attendees from across the globe.
The poster entitled “Measurement of gut permeability using fluorescent tracer agent technology“.
About MediBeacon Inc.
MediBeacon was co-founded in 2012 by Steven J. Hanley and Dr. Richard B. Dorshow to acquire the optical diagnostics and therapeutics program from Mallinckrodt. Mr. Hanley, former president of Covidien Mallinckrodt’s Imaging Solutions business unit, is MediBeacon’s CEO. Dr. Dorshow, who established and led development of the optical diagnostics and therapeutics program at Mallinckrodt, is MediBeacon’s chief scientific officer. The company holds numerous patents on its light-activated agents, which are the foundation of MediBeacon’s technology platform. Learn more about MediBeacon at www.medibeacon.com.